Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

被引：0
|
作者：
Jeeyun Lee
Kyung Hae Jung
Young Suk Park
Joong Bae Ahn
Sang Jun Shin
Seock-Ah Im
Do Youn Oh
Dong Bok Shin
Tae Won Kim
Namsu Lee
Jae Ho Byun
Yong Sang Hong
Joon Oh Park
Se Hoon Park
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Research Institute and Hospital,Oncology, Department of Medicine, Samsung Medical Center
[3] Yonsei University College of Medicine,Center for Colorectal Cancer, National Cancer Center
[4] Seoul National University College of Medicine,Department of Internal Medicine
[5] Gachon University Gil Medical Center,Department of Internal Medicine
[6] University of Ulsan College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Soon Chun Hyang University Hospital,Division of Oncology, Department of Medicine, Asan Medical Center
[8] The Catholic University of Korea,Division of Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Statin; Simvastatin; Irinotecan; Cetuximab; Lovastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [1] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Lee, Jeeyun
    Jung, Kyung Hae
    Park, Young Suk
    Ahn, Joong Bae
    Shin, Sang Jun
    Im, Seock-Ah
    Oh, Do Youn
    Shin, Dong Bok
    Kim, Tae Won
    Lee, Namsu
    Byun, Jae Ho
    Hong, Yong Sang
    Park, Joon Oh
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 657 - 663
  • [2] First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
    Koehne, Claus-Henning
    Hofheinz, Ralf
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Fernebro, Eva
    Gamelin, Erick
    DeCosta, Lucy
    Karthaus, Meinolf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (01) : 65 - 72
  • [3] A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
    Van Cutsem, E
    Pozzo, C
    Starkhammar, H
    Dirix, L
    Terzoli, E
    Cognetti, E
    Humblet, Y
    Garufi, C
    Filez, L
    Gruia, G
    Cote, C
    Barone, C
    ANNALS OF ONCOLOGY, 1998, 9 (11) : 1199 - 1204
  • [4] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
  • [5] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Juan José Reina
    Jorge Aparicio
    Javier Salvador
    José María Puerto Pica
    Antonio Rueda
    Antonio Lorenzo
    Carlos González de la Puente
    Pablo Borrega
    José Andrés Moreno-Nogueira
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 339 - 345
  • [6] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
  • [7] Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
    Kalofonos, HP
    Aravantinos, G
    Kosmidis, P
    Papakostas, P
    Economopoulos, T
    Dimopoulos, M
    Skarlos, D
    Bamias, A
    Pectasides, D
    Chalkidou, S
    Karina, M
    Koutras, A
    Samantas, E
    Bacoyiannis, C
    Samelis, GF
    Basdanis, G
    Kalfarentzos, F
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 869 - 877
  • [8] Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
    Aranda, E.
    Valladares, M.
    Martinez-Villacampa, M.
    Benavides, M.
    Gomez, A.
    Massutti, B.
    Marcuello, E.
    Constenla, M.
    Camara, J. C.
    Carrato, A.
    Duenas, R.
    Reboredo, M.
    Navarro, M.
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2009, 20 (02) : 251 - 257
  • [9] Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial
    Souglakos, J
    Pallis, A
    Kakolyris, S
    Mavroudis, D
    Androulakis, N
    Kouroussis, C
    Agelaki, S
    Xenidis, N
    Milaki, G
    Georgoulias, V
    ONCOLOGY, 2005, 69 (05) : 384 - 390
  • [10] A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
    Sun Jin Sym
    Junshik Hong
    Jinny Park
    Eun Kyung Cho
    Jae Hoon Lee
    Yeon Ho Park
    Woon Ki Lee
    Min Chung
    Hyung-Sik Kim
    Se Hoon Park
    Dong Bok Shin
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 481 - 488
12345